For the first time ever, a Phase III clinical trial of an HIV vaccine has seen some success. Initial results from the trial, dubbed RV144, showed that a combination of Sanofi-Pasteur’s Alvac and VaxGen’s AidsVAX B/E cut the risk of HIV infection by 31 per cent.